JP Morgan Chase’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
Other funds holding ABUS
JP Morgan Chase's ABUS Position: Q3 2026 in Review
JP Morgan Chase increased its Arbutus Biopharma (ABUS) stake by 13% in Q3 2026, buying an estimated $59.3K and bringing the position to 110,521 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #5193.
JP Morgan Chase first reported a position in ABUS in Q2 2015 and has held it in 39 quarters since. The position peaked at $2.93M in Q4 2024. 214 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.
- JP Morgan Chase held 110,521 shares of Arbutus Biopharma worth $518K as of Q3 2026.
- JP Morgan Chase bought 12,297 Arbutus Biopharma shares in Q3 2026, an estimated $59.3K.
- Arbutus Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #5193 holding.
- JP Morgan Chase first reported a position in Arbutus Biopharma in Q2 2015 and has held it in 39 quarters since.
- JP Morgan Chase's Arbutus Biopharma position peaked at $2.93M in Q4 2024.
- 214 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.